Lista de obras - Svetlana I. Gavrilova - Dominio Público Uruguay

Alpha-2 macroglobulin gene in early- and late-onset Alzheimer disease

artículo científico publicado en 1999

Autoantibodies to beta-amyloid and neurotransmitters in patients with Alzheimer's disease and senile dementia of the Alzheimer type

artículo científico publicado en 2001

Cerebrolysin in the therapy of mild cognitive impairment and dementia due to Alzheimer's disease: 30 years of clinical use

artículo científico publicado en 2020

Clinical heterogeneity of dementias of the Alzheimer's type ⬇️

artículo científico publicado el 1 de septiembre de 1991

Content of autoantibodies to bradykinin and beta-amyloid(1-42) as a criterion for biochemical differences between Alzheimer's dementias.

artículo científico publicado en 2003

Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study

artículo científico publicado en 2008

Efficacy and safety of Ginkgo biloba extract EGb 761 in mild cognitive impairment with neuropsychiatric symptoms: a randomized, placebo-controlled, double-blind, multi-center trial

artículo científico publicado en 2014

Helping carers to care--the 10/66 dementia research group's randomized control trial of a caregiver intervention in Russia

artículo científico publicado en 2009

Prognosis of mild cognitive impairment syndrome: data from a two-year clinical follow-up study.

artículo científico publicado en 2008

Some blood biochemistry parameters during the cholinergic treatment of Alzheimer's disease.

artículo científico publicado en 2001

Specificity of the neuropsychological syndromes of the disturbance of higher mental functions in Alzheimer's disease and senile dementia

artículo científico publicado en 1992

The Evolution of Diagnostic Boundaries of Alzheimer’s Disease and Novel Therapeutic Options

artículo científico publicado en 2022

The angiotensin-converting enzyme gene as a possible risk or protective factor in Alzheimer's disease.

artículo científico publicado en 2001

The protocols for the 10/66 dementia research group population-based research programme

artículo científico publicado en 2007

[Delayed effects of cerebrolysin in the prevention of cognitive impairment progression in the first degree relatives of patients with Alzheimer's disease: the role of the ApoE genotype]

scientific article published on 01 January 2020

[Immunological variants of amnestic mild cognitive impairment]

artículo científico publicado en 2020

[The use of neuroprotectors in the treatment of late depression]

scientific article published on 01 January 2020

Lista de obras de Svetlana I. Gavrilova

Alpha-2 macroglobulin gene in early- and late-onset Alzheimer disease

Autoantibodies to beta-amyloid and neurotransmitters in patients with Alzheimer's disease and senile dementia of the Alzheimer type

Cerebrolysin in the therapy of mild cognitive impairment and dementia due to Alzheimer's disease: 30 years of clinical use

Clinical heterogeneity of dementias of the Alzheimer's type ⬇️

Content of autoantibodies to bradykinin and beta-amyloid(1-42) as a criterion for biochemical differences between Alzheimer's dementias.

Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study

Efficacy and safety of Ginkgo biloba extract EGb 761 in mild cognitive impairment with neuropsychiatric symptoms: a randomized, placebo-controlled, double-blind, multi-center trial

Helping carers to care--the 10/66 dementia research group's randomized control trial of a caregiver intervention in Russia

Prognosis of mild cognitive impairment syndrome: data from a two-year clinical follow-up study.

Some blood biochemistry parameters during the cholinergic treatment of Alzheimer's disease.

Specificity of the neuropsychological syndromes of the disturbance of higher mental functions in Alzheimer's disease and senile dementia

The Evolution of Diagnostic Boundaries of Alzheimer’s Disease and Novel Therapeutic Options

The angiotensin-converting enzyme gene as a possible risk or protective factor in Alzheimer's disease.

The protocols for the 10/66 dementia research group population-based research programme

[Delayed effects of cerebrolysin in the prevention of cognitive impairment progression in the first degree relatives of patients with Alzheimer's disease: the role of the ApoE genotype]

[Immunological variants of amnestic mild cognitive impairment]

[The use of neuroprotectors in the treatment of late depression]